[Increased effectiveness of cytosatic therapy by promoting absorption of Ehrlich ascites with 1-phenyl-2-(p-hydroxyphenyl)-3,5-dioxo-4-n-butylpyrazolidine monohydrate].
D000818:Animals; D000970:Antineoplastic Agents; D000983:Antipyrine; D001201:Ascites; D002286:Carcinoma, Ehrlich Tumor; D010653:Phenylbutazone
D000970:Antineoplastic Agents; D010653:Phenylbutazone; D000983:Antipyrine
ANTINEOPLASTIC AGENTS; CARCINOMA, EHRLICH TUMOR; PHENYLBUTAZONE